Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
An affiliate of TWST filed a notice to sell 2,238 shares of common stock through Fidelity Brokerage Services on 07/23/2026 on NASDAQ, with an indicated value of $210,132.53. The shares relate to restricted stock vesting on 07/22/2026, treated as compensation.
The filing also lists prior sales in the past three months by Patrick Finn: 2,321 shares for $141,026.51 on 04/23/2026, 2,844 shares for $162,531.19 on 05/04/2026, and 4,160 shares for $221,547.45 on 05/21/2026.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,399 shares of common stock on July 9, 2026 at $94.334 per share. According to the disclosure, the sale was required to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Laponis directly holds 110,276 shares of Twist Bioscience common stock.
TWST-related filing: A Form 144 notice reports insider sales of Common stock by Adam Laponis. The filing lists multiple dispositions during April–May 2026 with per-trade share counts and proceeds recorded. It also shows a planned/security line item for Common with a 07/08/2025 vesting reference.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026. After this sale, she directly holds 824,039 common shares. The filing also lists outstanding employee stock options, including 16,470 options exercisable at $8.82 expiring in 2027 and 64,950 options at $67.85 expiring in 2030. The transactions were made under a pre-established Rule 10b5-1 trading plan.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock. On June 24, 2026, Cho sold 14,205 shares at $89.75 per share. After this transaction, he continues to hold 105,141 shares directly.
The filing notes that this sale was carried out under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026, indicating the trade was pre-planned rather than timed at discretion, which often signals routine portfolio management rather than a change in outlook.
Emily M. Leproust reported a series of sales of common stock between 04/21/2026 and 06/22/2026.
Transactions listed include 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46, along with multiple other dated sales and dollar amounts shown in the filing.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported a small mandated share sale tied to equity compensation. On June 22, 2026, she sold 291 shares of common stock at $87.3224 per share solely to cover tax withholding on vesting Restricted Stock Units. After this tax-related transaction, she directly held 120,414 shares of Twist Bioscience common stock.
Twist Bioscience Corp executive Dennis Cho reported a mandated sale of 346 shares of Common Stock. The shares were sold at an average price of $87.3224 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
According to the filing footnote, this was a required "sell to cover" transaction and not a discretionary trade by Cho. Following this tax-related sale, he directly owned 119,346 shares of Twist Bioscience Common Stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 1,688 shares of common stock at $87.3224 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
After this transaction, Leproust directly holds 842,919 shares of Twist Bioscience common stock. She also retains employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share that are outstanding and expire on August 31, 2030.
Twist Bioscience-related reporting person reported sales of Common Stock in multiple transactions. The largest single sale listed was 14,205 shares for $990,798.75 on 05/29/2026, with additional sales of 1,962 shares ($112,125.95), 1,642 shares ($87,447.34), 402 shares ($28,077.37), and 346 shares ($30,213.55) on the dates shown.